High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML). [electronic resource]
Producer: 20150218Description: 1685-94 p. digitalISSN:- 1432-0584
- ADP-ribosyl Cyclase 1
- Adolescent
- Adult
- Antigens, CD34 -- analysis
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Cell Separation -- methods
- Chromosome Aberrations
- Consolidation Chemotherapy
- Core Binding Factor Alpha 2 Subunit -- genetics
- Cytarabine -- administration & dosage
- Daunorubicin -- administration & dosage
- Female
- Flow Cytometry -- methods
- Humans
- In Situ Hybridization, Fluorescence
- Kaplan-Meier Estimate
- Leukemia, Myeloid, Acute -- drug therapy
- Male
- Middle Aged
- Neoplasm, Residual
- Neoplastic Stem Cells -- chemistry
- Oncogene Proteins, Fusion -- genetics
- Prognosis
- RUNX1 Translocation Partner 1 Protein
- Young Adult
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.